BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Erkan D, Salmon JE. The Role of Complement Inhibition in Thrombotic Angiopathies and Antiphospholipid Syndrome. Turk J Haematol 2016;33:1-7. [PMID: 27020721 DOI: 10.4274/tjh.2015.0197] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
Number Citing Articles
1 Silver RM. Catastrophic antiphospholipid syndrome and pregnancy. Semin Perinatol 2018;42:26-32. [PMID: 29179957 DOI: 10.1053/j.semperi.2017.11.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
2 Bezerra AS, Wroclawski CK, Lorber GR, Filho CC. Secondary vasculopathy due to catastrophic antiphospholipid syndrome. Hematol Transfus Cell Ther 2021:S2531-1379(21)01290-6. [PMID: 34836847 DOI: 10.1016/j.htct.2021.09.012] [Reference Citation Analysis]
3 Erton ZB, Erkan D. Treatment advances in antiphospholipid syndrome: 2022 update. Current Opinion in Pharmacology 2022;65:102212. [DOI: 10.1016/j.coph.2022.102212] [Reference Citation Analysis]
4 Cheng C, Cheng GY, Denas G, Pengo V. Arterial thrombosis in antiphospholipid syndrome (APS): Clinical approach and treatment. A systematic review. Blood Rev 2021;48:100788. [PMID: 33341301 DOI: 10.1016/j.blre.2020.100788] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Durigutto P, Grossi C, Borghi MO, Macor P, Pregnolato F, Raschi E, Myers MP, de Groot PG, Meroni PL, Tedesco F. New insight into antiphospholipid syndrome: antibodies to β2glycoprotein I-domain 5 fail to induce thrombi in rats. Haematologica 2019;104:819-26. [PMID: 30442725 DOI: 10.3324/haematol.2018.198119] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
6 Ge Y, Zhang Z. Effect of Tumor Red Blood Cell Immunity and Tumor Cell Cycle in Mice Bearing Solid Liver Cancer with Intelligent Cancer Zhongning Therapeutic Apparatus. J Healthc Eng 2021;2021:3329800. [PMID: 34194680 DOI: 10.1155/2021/3329800] [Reference Citation Analysis]
7 Tedesco F, Borghi MO, Gerosa M, Chighizola CB, Macor P, Lonati PA, Gulino A, Belmonte B, Meroni PL. Pathogenic Role of Complement in Antiphospholipid Syndrome and Therapeutic Implications. Front Immunol 2018;9:1388. [PMID: 29971066 DOI: 10.3389/fimmu.2018.01388] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
8 Velásquez M, Rojas M, Abrahams VM, Escudero C, Cadavid ÁP. Mechanisms of Endothelial Dysfunction in Antiphospholipid Syndrome: Association With Clinical Manifestations. Front Physiol 2018;9:1840. [PMID: 30627104 DOI: 10.3389/fphys.2018.01840] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
9 Erkan D. Expert Perspective: Management of Microvascular and Catastrophic Antiphospholipid Syndrome. Arthritis Rheumatol 2021. [PMID: 34114366 DOI: 10.1002/art.41891] [Reference Citation Analysis]
10 Sevim E, Willis R, Erkan D. Is there a role for immunosuppression in antiphospholipid syndrome? Hematology Am Soc Hematol Educ Program 2019;2019:426-32. [PMID: 31808842 DOI: 10.1182/hematology.2019000073] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
11 Högdén A, Antovic A, Berg E, Bremme K, Chaireti R. Obstetric outcomes in patients with primary thrombotic and obstetric antiphospholipid syndrome and its relation to the antiphospholipid antibody profile. Lupus 2019;28:868-77. [DOI: 10.1177/0961203319852155] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
12 Shochet L, Kanellis J, Simpson I, Ta J, Mulley W. De novo thrombotic microangiopathy following simultaneous pancreas and kidney transplantation managed with eculizumab. Nephrology (Carlton). 2017;22 Suppl 1:23-27. [PMID: 28176480 DOI: 10.1111/nep.12936] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
13 Yadalam PK, Rajapandian K, Ravishankar PL, Vartharajan K, Subramaniam S, Dinakar M. Evaluation of anticardiolipin antibodies in tobacco users and non-tobacco users with severe chronic periodontal disease. J Int Soc Prev Community Dent 2016;6:256-60. [PMID: 27382544 DOI: 10.4103/2231-0762.183115] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
14 Nauseef JT, Lim HI, DeSancho MT. Successful outcome with eculizumab treatment in a patient with antiphospholipid syndrome presenting with an unusual thrombotic storm. J Thromb Thrombolysis 2021;52:597-600. [PMID: 33222114 DOI: 10.1007/s11239-020-02343-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Cervera R, Rodríguez-pintó I, Legault K, Erkan D. 16th International Congress on Antiphospholipid Antibodies Task Force Report on Catastrophic Antiphospholipid Syndrome. Lupus 2020;29:1594-600. [DOI: 10.1177/0961203320951260] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Tinti MG, Carnevale V, Inglese M, Molinaro F, Bernal M, Migliore A, De Cata A. Eculizumab in refractory catastrophic antiphospholipid syndrome: a case report and systematic review of the literature. Clin Exp Med 2019;19:281-8. [PMID: 31214910 DOI: 10.1007/s10238-019-00565-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
17 Radin M, Cecchi I, Rubini E, Foddai SG, Barinotti A, Menegatti E, Roccatello D, Sciascia S. Treatment of antiphospholipid syndrome. Clin Immunol 2020;221:108597. [PMID: 32961331 DOI: 10.1016/j.clim.2020.108597] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Hysa E, Cutolo CA, Gotelli E, Paolino S, Cimmino MA, Pacini G, Pizzorni C, Sulli A, Smith V, Cutolo M. Ocular microvascular damage in autoimmune rheumatic diseases: The pathophysiological role of the immune system. Autoimmun Rev 2021;20:102796. [PMID: 33722750 DOI: 10.1016/j.autrev.2021.102796] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Iguchi D, Mizuno M, Suzuki Y, Sakata F, Maruyama S, Okada A, Okada H, Ito Y. Anti-C5a complementary peptide mitigates zymosan-induced severe peritonitis with fibrotic encapsulation in rats pretreated with methylglyoxal. American Journal of Physiology-Renal Physiology 2018;315:F1732-46. [DOI: 10.1152/ajprenal.00172.2018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
20 Signorelli F, Balbi GGM, Domingues V, Levy RA. New and upcoming treatments in antiphospholipid syndrome: A comprehensive review. Pharmacological Research 2018;133:108-20. [DOI: 10.1016/j.phrs.2018.04.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
21 Stanescu C, Andronesi AG, Jurcut C, Gherghiceanu M, Vornicu A, Burcea FA, Andronesi TD, Lupusoru GE, Iliuta L, Sorohan BM, Obrisca B, Ismail G. Successful Treatment of Catastrophic Antiphospholipid Syndrome Using Rituximab: Case Report and Review of the Literature. Medicina (Kaunas) 2021;57:912. [PMID: 34577835 DOI: 10.3390/medicina57090912] [Reference Citation Analysis]
22 Carlisi M, Mancuso S, Caimi G, Siragusa S. Thrombotic risk in paroxysmal nocturnal hemoglobinuria-like (PNH-like) phenotype. Clin Hemorheol Microcirc 2021;79:491-503. [PMID: 32116238 DOI: 10.3233/CH-190735] [Reference Citation Analysis]
23 Dobrowolski C, Erkan D. Treatment of antiphospholipid syndrome beyond anticoagulation. Clin Immunol 2019;206:53-62. [PMID: 29510235 DOI: 10.1016/j.clim.2018.03.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
24 Rodriguez-pintó I, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome: The current management approach. Best Practice & Research Clinical Rheumatology 2016;30:239-49. [DOI: 10.1016/j.berh.2016.07.004] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
25 Merrill JT, Erkan D, Winakur J, James JA. Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications. Nat Rev Rheumatol 2020;16:581-9. [PMID: 32733003 DOI: 10.1038/s41584-020-0474-5] [Cited by in Crossref: 81] [Cited by in F6Publishing: 70] [Article Influence: 40.5] [Reference Citation Analysis]
26 Palma LMP, Sridharan M, Sethi S. Complement in Secondary Thrombotic Microangiopathy. Kidney Int Rep 2021;6:11-23. [PMID: 33102952 DOI: 10.1016/j.ekir.2020.10.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
27 McDonnell T, Wincup C, Buchholz I, Pericleous C, Giles I, Ripoll V, Cohen H, Delcea M, Rahman A. The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS. Blood Rev 2020;39:100610. [PMID: 31471128 DOI: 10.1016/j.blre.2019.100610] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
28 Müller-Calleja N, Ritter S, Hollerbach A, Falter T, Lackner KJ, Ruf W. Complement C5 but not C3 is expendable for tissue factor activation by cofactor-independent antiphospholipid antibodies. Blood Adv 2018;2:979-86. [PMID: 29716893 DOI: 10.1182/bloodadvances.2018017095] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
29 Bommer M, Wölfle-Guter M, Bohl S, Kuchenbauer F. The Differential Diagnosis and Treatment of Thrombotic Microangiopathies. Dtsch Arztebl Int 2018;115:327-34. [PMID: 29875054 DOI: 10.3238/arztebl.2018.0327] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 3.7] [Reference Citation Analysis]
30 Andrade D, Cervera R, Cohen H, Crowther M, Cuadrado MJ, Canaud G, Garcia DA, Gerosa M, Ortel TL, Pengo V, Rahman A, Salmon JE, Willis R, Woller SC, Erkan D, Lockshin MD, Tektonidou MG. 15th International Congress on Antiphospholipid Antibodies Task Force on Antiphospholipid Syndrome Treatment Trends Report. In: Erkan D, Lockshin MD, editors. Antiphospholipid Syndrome. Cham: Springer International Publishing; 2017. pp. 317-38. [DOI: 10.1007/978-3-319-55442-6_18] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]